IL2 and amyotrophic lateral sclerosis: Previous studies have shown that low-dose IL-2 is well-tolerated and immunologically effective in patients with ALS (Camu et al., 2020), and Low-dose IL-2 promotes regulatory T-cell expansion and enhances the anti-inflammatory effects of regulatory T cells (Giovannelli et al., 2021).